These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31092402)

  • 1. First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study.
    Khot A; Brajanovski N; Cameron DP; Hein N; Maclachlan KH; Sanij E; Lim J; Soong J; Link E; Blombery P; Thompson ER; Fellowes A; Sheppard KE; McArthur GA; Pearson RB; Hannan RD; Poortinga G; Harrison SJ
    Cancer Discov; 2019 Aug; 9(8):1036-1049. PubMed ID: 31092402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling.
    Quin J; Chan KT; Devlin JR; Cameron DP; Diesch J; Cullinane C; Ahern J; Khot A; Hein N; George AJ; Hannan KM; Poortinga G; Sheppard KE; Khanna KK; Johnstone RW; Drygin D; McArthur GA; Pearson RB; Sanij E; Hannan RD
    Oncotarget; 2016 Aug; 7(31):49800-49818. PubMed ID: 27391441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
    Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ
    Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.
    Drygin D; Lin A; Bliesath J; Ho CB; O'Brien SE; Proffitt C; Omori M; Haddach M; Schwaebe MK; Siddiqui-Jain A; Streiner N; Quin JE; Sanij E; Bywater MJ; Hannan RD; Ryckman D; Anderes K; Rice WG
    Cancer Res; 2011 Feb; 71(4):1418-30. PubMed ID: 21159662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CX-5461 inhibits RNA Pol I in blood cancers.
    Cancer Discov; 2014 Dec; 4(12):OF5. PubMed ID: 25477122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Copper-CX-5461: A novel liposomal formulation for a small molecule rRNA synthesis inhibitor.
    Leung AWY; Anantha M; Dragowska WH; Wehbe M; Bally MB
    J Control Release; 2018 Sep; 286():1-9. PubMed ID: 30016731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.
    Rebello RJ; Kusnadi E; Cameron DP; Pearson HB; Lesmana A; Devlin JR; Drygin D; Clark AK; Porter L; Pedersen J; Sandhu S; Risbridger GP; Pearson RB; Hannan RD; Furic L
    Clin Cancer Res; 2016 Nov; 22(22):5539-5552. PubMed ID: 27486174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
    Bywater MJ; Poortinga G; Sanij E; Hein N; Peck A; Cullinane C; Wall M; Cluse L; Drygin D; Anderes K; Huser N; Proffitt C; Bliesath J; Haddach M; Schwaebe MK; Ryckman DM; Rice WG; Schmitt C; Lowe SW; Johnstone RW; Pearson RB; McArthur GA; Hannan RD
    Cancer Cell; 2012 Jul; 22(1):51-65. PubMed ID: 22789538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma.
    Devlin JR; Hannan KM; Hein N; Cullinane C; Kusnadi E; Ng PY; George AJ; Shortt J; Bywater MJ; Poortinga G; Sanij E; Kang J; Drygin D; O'Brien S; Johnstone RW; McArthur GA; Hannan RD; Pearson RB
    Cancer Discov; 2016 Jan; 6(1):59-70. PubMed ID: 26490423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting RNA-Polymerase I in Both Chemosensitive and Chemoresistant Populations in Epithelial Ovarian Cancer.
    Cornelison R; Dobbin ZC; Katre AA; Jeong DH; Zhang Y; Chen D; Petrova Y; Llaneza DC; Steg AD; Parsons L; Schneider DA; Landen CN
    Clin Cancer Res; 2017 Nov; 23(21):6529-6540. PubMed ID: 28778862
    [No Abstract]   [Full Text] [Related]  

  • 11. CX-5461-loaded nucleolus-targeting nanoplatform for cancer therapy through induction of pro-death autophagy.
    Duo Y; Yang M; Du Z; Feng C; Xing C; Wu Y; Xie Z; Zhang F; Huang L; Zeng X; Chen H
    Acta Biomater; 2018 Oct; 79():317-330. PubMed ID: 30172068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours.
    Xu H; Di Antonio M; McKinney S; Mathew V; Ho B; O'Neil NJ; Santos ND; Silvester J; Wei V; Garcia J; Kabeer F; Lai D; Soriano P; Banáth J; Chiu DS; Yap D; Le DD; Ye FB; Zhang A; Thu K; Soong J; Lin SC; Tsai AH; Osako T; Algara T; Saunders DN; Wong J; Xian J; Bally MB; Brenton JD; Brown GW; Shah SP; Cescon D; Mak TW; Caldas C; Stirling PC; Hieter P; Balasubramanian S; Aparicio S
    Nat Commun; 2017 Feb; 8():14432. PubMed ID: 28211448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.
    DeAngelo DJ; Spencer A; Bhalla KN; Prince HM; Fischer T; Kindler T; Giles FJ; Scott JW; Parker K; Liu A; Woo M; Atadja P; Mishra KK; Ottmann OG
    Leukemia; 2013 Aug; 27(8):1628-36. PubMed ID: 23385375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
    Papadopoulos KP; Ben-Ami E; Patnaik A; Trone D; Li J; Demetri GD
    BMC Cancer; 2018 Aug; 18(1):790. PubMed ID: 30081867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis.
    Negi SS; Brown P
    Oncotarget; 2015 Jul; 6(20):18094-104. PubMed ID: 26061708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.
    Angevin E; Spitaleri G; Rodon J; Dotti K; Isambert N; Salvagni S; Moreno V; Assadourian S; Gomez C; Harnois M; Hollebecque A; Azaro A; Hervieu A; Rihawi K; De Marinis F
    Eur J Cancer; 2017 Dec; 87():131-139. PubMed ID: 29145039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis.
    Kusnadi EP; Trigos AS; Cullinane C; Goode DL; Larsson O; Devlin JR; Chan KT; De Souza DP; McConville MJ; McArthur GA; Thomas G; Sanij E; Poortinga G; Hannan RD; Hannan KM; Kang J; Pearson RB
    EMBO J; 2020 Nov; 39(21):e105111. PubMed ID: 32945574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The therapeutic potential of RNA Polymerase I transcription inhibitor, CX-5461, in uterine leiomyosarcoma.
    Kang CW; Hannan KM; Blackburn AC; Loh AHP; Hong KC; Yuan GJ; Hein N; Drygin D; Hannan RD; Coupland LA
    Invest New Drugs; 2022 Jun; 40(3):529-536. PubMed ID: 35201535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribosomal DNA copy loss and repeat instability in ATRX-mutated cancers.
    Udugama M; Sanij E; Voon HPJ; Son J; Hii L; Henson JD; Chan FL; Chang FTM; Liu Y; Pearson RB; Kalitsis P; Mann JR; Collas P; Hannan RD; Wong LH
    Proc Natl Acad Sci U S A; 2018 May; 115(18):4737-4742. PubMed ID: 29669917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PICT-1 triggers a pro-death autophagy through inhibiting rRNA transcription and AKT/mTOR/p70S6K signaling pathway.
    Chen H; Duo Y; Hu B; Wang Z; Zhang F; Tsai H; Zhang J; Zhou L; Wang L; Wang X; Huang L
    Oncotarget; 2016 Nov; 7(48):78747-78763. PubMed ID: 27729611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.